Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Lindus Health has gone all-in on all-in-one CRO offerings. Less than a month after launching its All-in-One Women's Health ...

Medtronic has reported revenue gains across several of its medical device franchises, leading the company to nudge up its ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

Venture capital fund Jupiter Bioventures is taking off with $70 million for a portfolio of cancer-adjacent biotech startups, ...

Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...

Citizen’s partnership will work with CZI’s Rare As One project, a research and funding network that includes multiple patient ...

Canadian CRO Innovaderm is looking to expand its operations across the pond with the hiring of Ina Zschocke, Ph.D., as ...

Incyte’s $750 million Escient Pharmaceuticals buyout has rapidly run into problems. Less than six months after closing the ...

An open-label extension study of the phase 3 ATTRibute-CM trial shows that acoramidis produced reductions of 36% and 34% in ...